The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
Open accessAbstract
Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development. We have recently defined the tumorigenic potential and clinical significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC). The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism. In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker α-fetoprotein and activation of mitogen-activated protein kinase. Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions. RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade. These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418
YAP1 increases organ size and expands undifferentiated progenitor cells
Camargo, F. D., Gokhale, S., Johnnidis, J. B., Fu, D., Bell, G. W., Jaenisch, R., & Brummelkamp, T. R. (2007) · Current Biology · doi:10.1016/j.cub.2007.10.039 · Cited by 1,252
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.030 · Cited by 1,065
Self-citationWu, S., Liu, Y., Zheng, Y., Dong, J., & Pan, D. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.007 · Cited by 640 · cited 2×
“…wherein, together with TEA domain (TEAD)/transcription enhancer factor family of transcription factors (for example, Scalloped), Yki could transactivate multiple gene targets such as cyclin E, diap1 and bantam microRNA (Thompson and Cohen, 2006; Bandura and Edgar, 2008; Wu et al., 2008).”
Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells
Hasanbasic, I., Cuerquis, J., Varnum, B., & Blostein, M. D. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00020.2004 · Cited by 156
Cited by
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R., & Halder, G. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 881
The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway
Hong, W., & Guan, K.-L. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.05.004 · Cited by 493
Self-citationYAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 488
YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers
Stein, C., Bardet, A. F., Roma, G., Bergling, S., Clay, I., Ruchti, A., Agarinis, C., Schmelzle, T., Bouwmeester, T., Schübeler, D., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005465 · Cited by 414
Hippo Pathway-independent Restriction of TAZ and YAP by Angiomotin
Chan, S. W., Lim, C. J., Chong, Y. F., Pobbati, A. V., Huang, C., & Hong, W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.212621 · Cited by 386
Self-citationA targetable LIFR−NF-κB−LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
Yao, F., Deng, Y., Zhao, Y., Mei, Y., Zhang, Y., Liu, X., Martinez, C., Su, X., Rosato, R. R., Teng, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27452-9 · Cited by 322
ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., Herr, R., Brabletz, S., Stemmler, M. P., & Brabletz, T. (2016) · Nature Communications · doi:10.1038/ncomms10498 · Cited by 305
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 270
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Emerging roles of TEAD transcription factors and its coactivators in cancers
Pobbati, A. V., & Hong, W. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23788 · Cited by 253
Self-citationBrodowska, K., Al-Moujahed, A., Marmalidou, A., Meyer zu Horste, M., Cichy, J., Miller, J. W., Gragoudas, E., & Vavvas, D. G. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.04.011 · Cited by 220
Weiler, S. M. E., Pinna, F., Wolf, T., Lutz, T., Geldiyev, A., Sticht, C., Knaub, M., Thomann, S., Bissinger, M., Wan, S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.018 · Cited by 155
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82
The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells
Gobbi, G., Donati, B., Do Valle, I. F., Reggiani, F., Torricelli, F., Remondini, D., Castellani, G., Ambrosetti, D. C., Ciarrocchi, A., & Sancisi, V. (2019) · Oncogene · doi:10.1038/s41388-019-0924-1 · Cited by 69
Wong, K.-F., Liu, A. M., Hong, W., Xu, Z., & Luk, J. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12760 · Cited by 63
Self-citation
Metadata
- Authors
- Xu, M. Z., Chan, S. W., Liu, A. M., Wong, K. F., Fan, S. T., Chen, J., Poon, R. T., Zender, L., Lowe, S. W., Hong, W., & Luk, J. M.
- Venue
- Oncogene
- Published
- 2010-11-15
- Volume
- 30
- Issue
- 10
- Pages
- 1229-1240
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1984350114
- Cited by
- 228
- References
- 6
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.